Final Announcement:

Impact of COVID-19 on clinical trials
Wednesday May 6, 2020, 10-12 am
Virtual Seminar

The COVID-19 pandemic hits not only societies around the world hard but also clinical trials. Trials are affected to a different degree, depending on the indication, site location, and trial stage. For some trials, the impact can be substantial. Therefore, it is time to talk about this impact and mitigation steps.

This will be the first virtual seminar organized by the BBS, so it is a bit of an experiment still, especially for the panel discussion. Further virtual events on COVID-19 and other topics are planned in the near future.

Program

10:00-10:05 Welcome
Hans Ulrich Burger, BBS president

10:05-10:35 EMA perspective and guidance on COVID-19
Frank Pétavy, EMA

10:35-11:20 Industry perspective on COVID-19
Natalie Dimier, Roche
Mouna Akacha, Novartis
Cristina Sotto, J&J

11:20-11:30 Short Overview of Pharmaceutical Industry COVID-19 Biostatistics Working Group
Marcel Wolbers, Roche

11:30-11:40 Short overview on COVID-19 from the Cross-Industry Oncology Estimands Working Group
Evgeny Degtyarev, Novartis

11:40-12:00 Panel Discussion
All presenters

12:00 Closure of the meeting
Hans Ulrich Burger, BBS president